Evaluation of [18F]FLT PET/CT as an early predictor of outcome in pediatric solid tumors
Study ID: STU-2019-0627
Summary
The experimental [18F]FLT-PeT/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PeT/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
To assess if percentage change in [18F]FLT PeT/CT quantitative parameters (SuV max, or SuV peak or proliferative tumor volume) after 2 cycles of chemotherapy can predict progression free survival at 1 and 2 years in pediatric patients with newly diagnosed solid tumors
